| Human | BMND8 | 100188854 | bone mineral density quantiative trait locus 8 | Postmenopausal osteoporosis |
| Human | BMND7 | 100188853 | bone mineral density quantiative trait locus 7 | Postmenopausal osteoporosis |
| Human | IL1F6 | 27179 | interleukin 36, alpha | A functional IL-6 polymorphism has been weakly associated with level of peak bone mineral density and the rate of forearm trabecular postmenopausal bone loss in a cohort of women |
| Human | TNFSF11 | 8600 | tumor necrosis factor (ligand) superfamily, member 11 | In postmenopausal osteoporosis, TNFSF11 gene promoter polymorphisms -290C>T, -643C>T and -693G>C play a functional role in the genetic regulation of bone mineral density REVIEW: role of these molecules in immunology and skeletal remodelling and assess their involvement in diseases of bones and joints, including rheumatoid arthritis, Paget's disease, post-menopausal osteoporosis and malignant bone diseases |
| Human | PDLIM4 | 8572 | PDZ and LIM domain 4 | Postmenopausal osteoporosis |
| Human | VDR | 7421 | vitamin D (1,25- dihydroxyvitamin D3) receptor | Postmenopausal osteoporosis Significant association between VDR genotype and postmenopausal osteoporosis in Chinese women was observed in this study |
| Human | TNFRSF11B | 4982 | tumor necrosis factor receptor superfamily, member 11b | Sequence variations in the promoter in patients with postmenopausal osteoporosis REVIEW: role of these molecules in immunology and skeletal remodelling and assess their involvement in diseases of bones and joints, including rheumatoid arthritis, Paget's disease, post-menopausal osteoporosis and malignant bone diseases |
| Human | NPPB | 4879 | natriuretic peptide B | A promoter variation of this protein has an association with low bone-mineral density and rapid postmenopausal bone loss Title:Association of the -381T/C promoter variation of the brain natriuretic peptide gene with low bone-mineral density and rapid postmenopausal bone loss.|Association:Y|Conclusion:These results suggest that variation of BNP may be an important determinant of postmenopausal osteoporosis, in part through the mechanism of accelerated postmenopausal bone loss. |
| Human | LRP5 | 4041 | low density lipoprotein receptor-related protein 5 | Postmenopausal osteoporosis |
| Human | IL6 | 3569 | interleukin 6 (interferon, beta 2) | Postmenopausal osteoporosis |
| Human | ICAM1 | 3383 | intercellular adhesion molecule 1 | polymorphisms of ICAM1 may confer susceptibility to postmenopausal osteoporosis in women, and that of GJA4 to osteoporosis in men |
| Human | HP | 3240 | haptoglobin | genotype as a risk factor for postmenopausal osteoporosis |
| Human | ESR2 | 2100 | estrogen receptor 2 (ER beta) | lack of effect of RsaI polymorphism on bone mineral density and response to alendronate therapy in postmenopausal osteoporosis |
| Human | ESR1 | 2099 | estrogen receptor 1 | Estrogen receptor alpha genotype associations were statistically significant in explaining rate of perimenopausal bone loss and bone turnover |
| Human | COL1A2 | 1278 | collagen, type I, alpha 2 | Postmenopausal osteoporosis |
| Human | COL1A1 | 1277 | collagen, type I, alpha 1 | Postmenopausal osteoporosis |
| Human | CNR2 | 1269 | cannabinoid receptor 2 (macrophage) | polymorphisms of CNR2 may confer susceptibility to postmenopausal osteoporosis in women, and that of GJA4 to osteoporosis in men |
| Human | CNR1 | 1268 | cannabinoid receptor 1 (brain) | No convincing association is found for cannabinoid receptor type 1 (Cnr1) in a systematic genetic association study in a human sample of postmenopausal osteoporosis patients and matched female controls |
| Human | CALCR | 799 | calcitonin receptor | Postmenopausal osteoporosis |